Investigational drug · Phase 3
CHIKV VLP vaccine
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Chikungunya Virus.
Phase 3Last checked: Nov 20, 2026Latest source record: Nov 13, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
8
Any phase or sponsor naming "CHIKV VLP vaccine"
First trial start
2025
Jun 5, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "CHIKV VLP vaccine", any sponsor or status.
Conditions studied
As listed on its trial records.
- Chikungunya Virus
Largest trials
Live from ClinicalTrials.gov: studies naming "CHIKV VLP vaccine" as an intervention, largest first.
- An Efficacy, Safety, and Immunogenicity Study of CHIKV VLP Vaccine for the Prevention of Chikungunya Disease in Adolescents and AdultsPivotal-lookingRecruiting
Bavarian NordicIndustry
NCT07467707 · 6,144 participants (planned) · Start May 26, 2026 · Primary completion May 2030
Drug: CHIKV VLP vaccine; Placebo · For: Chikungunya Virus
Sites: Cebu City, Philippines; Kamphaeng Phet, Thailand; Hat Yai, Thailand
- A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0317 (CHIKV VLP Vaccine)Pivotal-lookingCompleted
Bavarian NordicIndustry
NCT05072080 · 3,258 participants · Start Sep 29, 2021 · Primary completion Apr 3, 2023
Drug: CHIKV VLP/adjuvant; Placebo · For: Chikungunya Virus
Sites: Huntsville, Alabama; Mobile, Alabama; Tempe, Arizona · 47 sites in all
- A Safety and Immunogenicity Study of CHIKV VLP Vaccine in Children.Pivotal-lookingActive, not recruiting
Bavarian NordicIndustry
NCT07003984 · 720 participants (planned) · Start Jun 5, 2025 · Primary completion Sep 2028
Drug: CHIKV VLP vaccine; Placebo · For: Chikungunya Virus
Sites: Fountain Valley, California; Washington D.C., District of Columbia; Miami, Florida · 15 sites in all
- Long-term Follow-up Study to Evaluate Safety and Immunogenicity of CHIKV VLP Single or Booster VaccinationPivotal-lookingActive, not recruiting
Bavarian NordicIndustry
NCT06007183 · 715 participants · Start Aug 30, 2023 · Primary completion Feb 2028
Drug: CHIKV VLP vaccine booster; Placebo booster · For: Chikungunya Virus Infection
Sites: Mobile, Alabama; Tempe, Arizona; Melbourne, Florida · 24 sites in all
- Trial of a Chikungunya Vaccine, PXVX0317 CHIKV-VLP, in Healthy AdultsPivotal-lookingCompleted
Bavarian NordicIndustry
NCT03483961 · 445 participants · Start Apr 18, 2018 · Primary completion Sep 14, 2020
Drug: CHIKV VLP/unadjuvanted; CHIKV VLP/adjuvanted and 1 more · For: Chikungunya Virus Infection
Sites: Lenexa, Kansas; Kansas City, Missouri; West Jordan, Utah
- Safety and Immunogenicity of CHIKV VLP Vaccine PXVX0317 in Adults ≥65 YearsPivotal-lookingCompleted
Bavarian NordicIndustry
NCT05349617 · 413 participants · Start May 12, 2022 · Primary completion Jun 19, 2023
Drug: CHIKV VLP/adjuvant; Placebo · For: Chikungunya Virus
Sites: Miami, Florida; Miami Lakes, Florida; St. Petersburg, Florida · 10 sites in all
- Trial for Safety and Immunogenicity of a Chikungunya Vaccine, VRC-CHKVLP059-00-VP, in Healthy AdultsPivotal-lookingCompleted
National Institute of Allergy and Infectious Diseases (NIAID)NIH
NCT02562482 · 400 participants · Start Nov 18, 2015 · Primary completion Mar 6, 2018
Drug: VRC-CHKVLP059-00-VP · For: Chikungunya Virus Infection
Sites: Santo Domingo, Dominican Republic; Pointe-à-Pitre, Guadeloupe; Port-au-Prince, Haiti · 6 sites in all
Bavarian NordicIndustry
NCT05065983 · 25 participants · Start Oct 11, 2021 · Primary completion May 5, 2022
Drug: CHIKV VLP, adjuvanted · For: Chikungunya Virus
Sites: Lenexa, Kansas
Newest research
PubMed records naming it or its code names, newest first.
- Chikungunya virus virus-like particle vaccine (VIMKUNYA) elicits cross-neutralization across CHIKV lineages and against other alphaviruses after just one dose.
Gardner CL, Brown NN, Brown JL, et al. · Vaccine 2026
- A chikungunya virus-like particle vaccine reduces chikungunya disease in cynomolgus macaques and protection is mediated by antibody transferred from vaccinated humans.
Coffey LL, Olstad KJ, Reader JR, et al. · NPJ Vaccines 2026
- A chikungunya virus-like particle vaccine reduces chikungunya disease in cynomolgus macaques and protection is mediated by antibody transferred from vaccinated humans.
Coffey LL, Olstad KJ, Reader JR, et al. · Res Sq 2025
- Safety and immunogenicity of an adjuvanted chikungunya virus virus-like particle (CHIKV VLP) vaccine in previous recipients of other alphavirus vaccines versus alphavirus vaccine-naive controls: an open-label, parallel-group, age-matched, sex-matched, phase 2 randomised controlled study.
Hamer MJ, McCarty JM, Pierson BC, et al. · Lancet Microbe 2025
- Chikungunya virus virus-like particle vaccine is well tolerated and immunogenic in chikungunya seropositive individuals.
McCarty JM, Bedell L, Mendy J, et al. · Vaccine 2023
- Immunological implications of diverse production approaches for Chikungunya virus-like particle vaccines.
Thompson D, Metz SW, Abad C, et al. · Vaccine 2022
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.